61
Participants
Start Date
March 22, 2021
Primary Completion Date
October 20, 2022
Study Completion Date
October 20, 2022
Posoleucel (formerly known as ALVR105) cells
Infusion
Placebo (visually identical to Posoleucel)
Infusion
NYU Langone Medical Center, New York
Weil Medical College - NY Presbyterian Hospital, New York
North Shore University Hospital, Manhasset
Erie County Medical Center, Buffalo
UPMC Montefiore Hospital, Pittsburgh
UPMC Pinnacle-Harrisburg Hospital, Harrisburg
University of Maryland Medical Center, Baltimore
John Hopkins Hospital, Baltimore
Inova Fairfax Medical Center, Falls Church
University of Virginia, Charlottesville
Virginia Commonwealth University, Richmond
Duke University, Durham
Medical University of South Carolina, Charleston
Piedmont Hospital, Atlanta
Cleveland Clinic Foundation, Cleveland
University of Cincinnati Hospital, Cincinnati
Indiana University Hospital, Indianapolis
University of Michigan Medical Center, Ann Arbor
University of Minnesota, Minneapolis
Loyola University Medical Center, Maywood
Northwestern University Transplant Center, Chicago
Washington University School of Medicine, St Louis
University of Kansas Hospital, Kansas City
University of Nebraska Medical Center, Omaha
Tulane University School of Medicine, New Orleans
Baylor University Medical Center, Dallas
UT Southwestern Medical Center, Dallas
Keck Medical Center of USC, Los Angeles
University of California, San Francisco Medical Center, San Francisco
Stanford University, Palo Alto
University of California Davis Medical Center, Sacramento
Harvard Medical School - Brigham & Women's Hospital, Boston
Rhode Island Hospital, Providence
Lead Sponsor
AlloVir
INDUSTRY